GAAP EPS loss widened to $(1.22) from $(1.10) year over year in Q2 2025 as R&D expenses rose 47.7% and G&A expenses climbed 48.8% compared to Q2 2024. VAX-31 vaccine program advanced with FDA expanded ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Key Points GAAP revenue surged to $4.0 million in Q2 2025, beating analyst expectations by 381.9%. GAAP net loss per share improved to $(0.50) in Q2 2025, slightly better than the estimated $(0.52).

Researchers at the University of New Mexico are preparing to launch a phase 1 clinical trial for an Alzheimer's vaccine after ...

Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

A phase 3, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for treatment of type 2 diabetes mellitus (T2DM) in children and adolescents.

Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...

The field of plasma cell disorders has advanced primarily because of the collective efforts of members in cooperative ...

Children’s Hospital of Orange County has completed its $300 million Southwest Tower, one of the larger healthcare projects in ...